We’re here to help.

Managing refractory complex partial seizures is challenging. That is why you have a care team who has helped patients like you before, to weigh the benefits and risks of different treatments.

If your care team prescribes VIGADRONE®, they will be committed to making sure you receive timely and consistent access to this important medication.

And, they will guide you through the necessary steps of:

  1. 1.Enrollment in the Vigabatrin REMS program, if you’re not already enrolled.
  2. 2.Filling out the patient information section of the Prescription Form.

You’ve been prescribed VIGADRONE®.
Now what?

To help you get started with VIGADRONE® (vigabatrin) Tablets, we have resources available, including:

A Medication Guide for the most important information to know to help answer some of the most common questions about VIGADRONE®

We know a lot about epilepsy and refractory complex partial seizures (CPS).

We are committed to helping patients with refractory complex partial seizures (CPS), a type of seizure that can have several different symptoms, such as a lapse in consciousness, disorientation, confusion or involuntary movements. Sometimes a person’s complex partial seizures cannot be controlled even after he or she has tried several medicines. When this happens, they are called refractory.

VIGADRONE® is a prescription medicine used along with other treatments in adults and children 2 years and older to help reduce the number of refractory CPS if you and your healthcare provider decide the possible benefit of taking VIGADRONE® is more important than the risk of vision loss.

We’re not alone.

For many years, there has been an ongoing, concerted effort to find better treatment and hopefully even a cure for epilepsy. We’re not there yet, but we’re not giving up.

For some people, the cause of refractory CPS may be unknown, or it may be linked to different conditions such as tuberous sclerosis complex (TSC). Additional information is available online.


The U.S. Food and Drug Administration (FDA) has approved a single shared system Risk Evaluation and Mitigation Strategy (REMS) for all vigabatrin products called the Vigabatrin REMS Program. It is required by the FDA to ensure informed risk-benefit decisions before initiating treatment and to ensure appropriate use of vigabatrin while patients are treated.

Visit the Vigabatrin REMS website for instructions and the FDA-mandated REMS forms.